- Home
- VTYX vs RDIB Comparison
VTYX vs RDIB Comparison
Compare VTYX & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- RDIB
- Stock Information
- Founded
- VTYX 2018
- RDIB 1937
- Country
- VTYX United States
- RDIB United States
- Employees
- VTYX N/A
- RDIB N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- RDIB Movies/Entertainment
- Sector
- VTYX Health Care
- RDIB Consumer Discretionary
- Exchange
- VTYX Nasdaq
- RDIB Nasdaq
- Market Cap
- VTYX 154.9M
- RDIB 140.2M
- IPO Year
- VTYX 2021
- RDIB N/A
- Fundamental
- Price
- VTYX $2.08
- RDIB $6.28
- Analyst Decision
- VTYX Buy
- RDIB
- Analyst Count
- VTYX 4
- RDIB 0
- Target Price
- VTYX $11.33
- RDIB N/A
- AVG Volume (30 Days)
- VTYX 1.9M
- RDIB 7.8K
- Earning Date
- VTYX 02-25-2025
- RDIB 11-14-2024
- Dividend Yield
- VTYX N/A
- RDIB N/A
- EPS Growth
- VTYX N/A
- RDIB N/A
- EPS
- VTYX N/A
- RDIB N/A
- Revenue
- VTYX N/A
- RDIB $197,270,000.00
- Revenue This Year
- VTYX N/A
- RDIB N/A
- Revenue Next Year
- VTYX N/A
- RDIB $14.40
- P/E Ratio
- VTYX N/A
- RDIB N/A
- Revenue Growth
- VTYX N/A
- RDIB N/A
- 52 Week Low
- VTYX $1.67
- RDIB $5.78
- 52 Week High
- VTYX $11.48
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- VTYX 45.64
- RDIB 41.52
- Support Level
- VTYX $1.83
- RDIB $5.78
- Resistance Level
- VTYX $2.61
- RDIB $6.40
- Average True Range (ATR)
- VTYX 0.18
- RDIB 0.64
- MACD
- VTYX -0.03
- RDIB -0.17
- Stochastic Oscillator
- VTYX 32.26
- RDIB 14.53
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.